Korby Howell, PA
Physician Assistant · Cortez, CONPI 1447743257
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $131,368 of the $181,892 with a category attached, or 72.2%. 20 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 50.9% of the total. 2025 is the largest year on record at $95,410, more than ten times the $223 reported in 2021. Among physician assistant clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 427 payments — averaging $425.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$93K
- AbbVie$62K
- E.r. Squibb & Sons, L.L.C.$11K
- Alkermes, Inc.$10K
- Braeburn Inc.$5K
- Indivior Inc.$112
- plus $501 from 14 others
What the payments were for
- Consulting fees$13,8858%
- Speaking & faculty fees$131,36872%
- Travel & lodging$28,67916%
- Food & beverage$7,8564%
- Education$1050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 152 | $92,589 |
| AbbVie | 166 | $62,076 |
| E.r. Squibb & Sons, L.L.C. | 29 | $11,405 |
| Alkermes, Inc. | 31 | $9,817 |
| Braeburn Inc. | 18 | $5,392 |
| Indivior Inc. | 5 | $112 |
| Otsuka America Pharmaceutical, Inc. | 5 | $103 |
| Supernus Pharmaceuticals, Inc. | 2 | $69 |
| USWM, LLC | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
| Amgen | 3 | $46 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Lundbeck LLC | 1 | $26 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Merck | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Dexcom, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$181,892 in reported general payments places this provider in the 95th percentile of 2,849 physician assistant providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 69 | $67,006 |
| CaplytaLumateperone Tosylate | 32 | $50,919 |
| Invega SustennaPaliperidone Palmitate | 16 | $39,002 |
| MounjaroTirzepatide | 21 | $32,917 |
| FarxigaDapagliflozin Propanediol | 37 | $23,350 |
| VraylarCariprazine Hcl | 12 | $21,508 |
| JardianceEmpagliflozin | 16 | $19,854 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $18,031 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 72 | $12,555 |
| EliquisApixaban | 11 | $9,906 |
| EntrestoSacubitril/Valsartan | 12 | $7,754 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,885 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $5,822 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,636 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,353 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $16 | $67,00669 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $92,589 | $50,91932 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Spiriva Respimat, Combivent Respimat | $16 | $36,66550 claims |
| Lilly USA, LLCMounjaro | $18 | $32,91721 claims |
| AbbVieVraylar, Synthroid | $62,076 | $22,44932 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,849 physician assistant providers in Colorado.
Other physician assistant in Cortez
- Donald MooreEnglewood$246K
- Neekan AeiniGreenwood Village$234K
- Heather FinlaysonLittleton$180K
- Kristen LervikDenver$131K
- Marissa Moritz-GuzikLouisville$94K
- Clayton LabaumeDurango$87K
- Emily FrischDenver$79K
- Daniel HumerLone Tree$69K
- Christine ZerrLittleton$68K
- Andrew GardnerDenver$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.